trigram

This is a table of type trigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

trigram	frequency
of the study	224
in patients with	146
x x x	135
data will be	129
will be performed	127
of the trial	121
in the study	121
will be used	118
the use of	111
as well as	109
patients will be	109
according to the	98
x a x	96
will be collected	88
a x a	88
will be conducted	86
the study will	85
study will be	83
based on the	80
respiratory distress syndrome	77
will not be	73
patients with covid	72
the control group	71
to the study	70
the primary outcome	66
will be recorded	66
one of the	66
standard of care	66
acute respiratory distress	66
will also be	65
in accordance with	65
the end of	63
the patient is	63
participants will be	61
be used to	58
the risk of	58
at any time	57
will be compared	57
of the following	57
randomized controlled trial	57
included in the	56
acute lung injury	55
the treatment of	55
analyses will be	55
the incidence of	54
in the trial	53
samples will be	53
critically ill patients	52
will be reported	52
the full protocol	51
proportion of patients	50
the number of	50
end of the	50
as part of	49
to assess the	49
will be provided	48
quality of life	48
in this study	48
is defined as	48
the time of	48
patients in the	47
and will be	47
be included in	47
part of the	47
the primary endpoint	47
the study intervention	46
randomised controlled trial	46
during the study	45
trial will be	45
the effect of	45
due to the	44
a total of	44
will be presented	44
in the icu	44
intensive care unit	44
analysis will be	43
of the intervention	43
at the time	43
accordance with the	43
will be assessed	42
will be considered	42
of the primary	42
in order to	42
will be included	42
the study protocol	41
will be done	41
the presence of	41
will be stored	40
if the patient	40
there is a	40
will be administered	40
of patients with	39
the trial is	39
the trial will	39
there is no	39
will be obtained	39
will be given	38
analysis of the	38
by the investigator	38
the study is	38
this study is	38
to evaluate the	38
in case of	38
the development of	37
access to the	37
in addition to	37
in critically ill	37
the investigator will	36
protocol for a	36
for at least	36
from the study	36
be used for	36
approved by the	36
the informed consent	35
this study will	35
with regard to	35
patients with acute	35
the proportion of	34
the results of	34
a systematic review	34
to participate in	34
chronic obstructive pulmonary	34
obstructive pulmonary disease	34
of this study	34
any of the	33
consent will be	33
randomization will be	33
this is a	33
will be taken	33
related to the	32
for the treatment	32
be compared between	32
participate in the	32
in the case	32
outcomes will be	31
study protocol for	31
the efficacy of	31
will be randomized	31
will be made	31
efficacy and safety	30
in the control	30
will be analyzed	30
will be recruited	30
of mechanical ventilation	30
severe acute respiratory	30
patients with severe	30
in this trial	29
there are no	29
the study team	29
day and day	29
at least one	29
is based on	29
the study and	29
in the treatment	29
of the data	29
in terms of	29
claims in published	28
group will be	28
de la recherche	28
to jurisdictional claims	28
published maps and	28
regard to jurisdictional	28
in published maps	28
hypoxic respiratory failure	28
an adverse event	28
maps and institutional	28
and institutional affiliations	28
within the first	28
remains neutral with	28
jurisdictional claims in	28
nature remains neutral	28
will be calculated	28
invasive mechanical ventilation	28
in the first	28
springer nature remains	28
the two groups	28
summary of the	28
approved the final	28
the sample size	28
neutral with regard	28
events will be	27
the intensive care	27
will be evaluated	27
the rate of	27
as soon as	27
statistical analysis plan	27
they will be	27
a summary of	27
will be followed	27
case report form	27
serious adverse events	27
the need for	27
will be asked	27
the principal investigator	26
participation in the	26
legally acceptable representative	26
the level of	26
and safety of	26
between the two	26
primary outcome is	26
will be the	26
ministry of health	26
the duration of	26
be recorded in	26
the first days	26
it will be	25
information will be	25
the investigator or	25
the management of	25
the occurrence of	25
and approved the	25
daily for days	25
p f ratio	25
patients who are	25
twice daily for	25
well as the	25
of the clinical	25
to the intervention	25
use of the	25
the start of	25
patients admitted to	25
of the patient	25
admitted to the	24
group will receive	24
the first h	24
elements of the	24
the impact of	24
of the key	24
will be analysed	24
be obtained from	24
the effects of	24
be performed by	24
associated with the	24
acute hypoxic respiratory	24
serves as a	24
the cure rct	24
written informed consent	24
version of the	24
of a study	24
the study drug	24
note springer nature	23
will be kept	23
of the full	23
the inclusion criteria	23
there will be	23
systematic review and	23
the treating physician	23
the research team	23
results will be	23
patients randomized to	23
data from the	23
this will be	23
acute respiratory syndrome	23
be carried out	23
for patients with	23
treatment will be	23
key elements of	22
as a summary	22
the intervention group	22
the key elements	22
defined as the	22
accessible from the	22
at the end	22
number of days	22
numbers to be	22
for more than	22
letter serves as	22
from the trials	22
familiar formatting has	22
the safety of	22
is attached as	22
of this material	22
compared between the	22
for the study	22
recorded in the	22
primary and secondary	22
the role of	22
as an additional	22
attached as an	22
this letter serves	22
the familiar formatting	22
in the interest	22
controlled trial date	22
the trials website	22
consent to participate	22
involved in the	22
an additional file	22
intervention and comparator	22
prior to the	22
has been eliminated	22
by the study	22
dissemination of this	22
formatting has been	22
expediting dissemination of	22
the severity of	22
design of the	21
the interest in	21
from the trial	21
the investigator must	21
in the intervention	21
interest in expediting	21
number of patients	21
control group will	21
more than days	21
have access to	21
be reported as	21
and exclusion criteria	21
reported to the	21
is expected to	21
in expediting dissemination	21
the case of	21
to the trial	21
the effectiveness of	21
sample size calculation	21
be stored in	21
no competing interests	21
lost to follow	20
the design of	20
which will be	20
will take place	20
the patient will	20
we will use	20
is associated with	20
a reduction in	20
risk factors for	20
informed consent form	20
the primary efficacy	20
for the trial	20
sample size of	20
in clinical trials	20
world health organization	20
the university of	20
full protocol is	20
read and approved	20
to the protocol	20
length of stay	20
protocol is attached	20
be conducted in	19
for the primary	19
declare that they	19
indoor residual spraying	19
to reduce the	19
the trial and	19
accompanies this paper	19
a study protocol	19
sensorineural hearing loss	19
that they have	19
will be assigned	19
supplementary information accompanies	19
review and meta	19
prior to randomization	19
have no competing	19
be asked to	19
they have no	19
the onset of	19
the course of	19
primary efficacy outcome	19
as described in	19
and in the	19
authors declare that	19
this paper at	19
summary of a	19
paper at https	19
information accompanies this	19
randomized to ravulizumab	19
the live home	19
the clinical trial	19
the authors declare	19
of study drug	19
randomized clinical trial	19
during the first	18
good clinical practice	18
data monitoring committee	18
inclusion and exclusion	18
to be randomised	18
duration of the	18
cytokine release syndrome	18
to clinical improvement	18
will be informed	18
by the research	18
responsible for the	18
to ravulizumab bsc	18
patients with a	18
the prevention of	18
the data will	18
of the first	18
be followed up	18
will have the	18
randomly assigned to	18
structured summary of	18
the administration of	18
at baseline and	18
the statistical analysis	18
information about the	18
will be summarized	18
will be in	18
the final manuscript	18
a randomized controlled	17
will be measured	17
the aim of	17
the completion of	17
the primary analysis	17
compared with bsc	17
be analyzed using	17
enrolled in the	17
with bsc alone	17
hospitalized patients with	17
this trial will	17
is responsible for	17
be reported to	17
treatment of covid	17
the intervention and	17
sudden sensorineural hearing	17
results of the	17
study is to	17
for the prevention	17
the analysis of	17
be performed using	17
arterial blood gas	17
will be carried	17
a structured summary	17
informed consent will	17
of the event	17
in the intensive	17
in the crf	17
the efficacy and	17
variables will be	17
will only be	17
serious adverse event	17
the clinical study	17
positive airway pressure	17
the corresponding author	17
a randomised controlled	17
the study physician	16
can be used	16
a combination of	16
jours de traitement	16
assessment of the	16
subject will be	16
a period of	16
the study period	16
by the treating	16
patients with ards	16
with severe covid	16
the ethics committee	16
to the sponsor	16
each of the	16
consistent with the	16
as a result	16
during the trial	16
on day and	16
based on a	16
be submitted to	16
will be published	16
the absence of	16
patients that are	16
will be blinded	16
will be stratified	16
the option to	16
provided by the	16
for all patients	16
the application of	16
time to clinical	16
of at least	16
be performed in	16
icu pilot rct	16
patients will receive	16
will be excluded	16
available from the	16
been shown to	16
to study if	16
for patients randomized	16
associated with a	15
will have access	15
to one of	15
completion of the	15
total of patients	15
will be documented	15
of the disease	15
interpretation of data	15
primary evaluation period	15
in the design	15
to the control	15
the experimental group	15
documented in the	15
hypothesis is that	15
in relation to	15
for a randomised	15
ketamine will be	15
sample size is	15
no more than	15
reduction in the	15
the case report	15
a minimum of	15
start of the	15
compared to the	15
approval of the	15
untoward medical occurrence	15
of patients who	15
in the ecrf	15
of these events	15
day will be	15
in indigenous infants	15
have to be	15
blinded to the	15
the balance main	15
from the corresponding	15
be collected at	15
all data will	15
are defined as	15
standard protocol items	15
be performed at	15
continuous positive airway	15
at least years	15
within days of	15
saes will be	15
course of the	15
members of the	15
of inspired oxygen	15
development of the	15
for this study	15
in the event	15
withdraw from the	15
to the icu	15
it has been	14
soon as possible	14
will be available	14
and management of	14
with the use	14
has been shown	14
days will be	14
the discretion of	14
investigator or designee	14
for adverse events	14
participants in the	14
are as follows	14
of adverse events	14
sequential organ failure	14
have the option	14
of this trial	14
be used as	14
contributed to the	14
intervention will be	14
reduce the risk	14
in the balance	14
will be submitted	14
this trial is	14
organ failure assessment	14
will be randomly	14
corresponding author on	14
obtained from the	14
treatment with ravulizumab	14
the investigator and	14
at the same	14
of health and	14
the study design	14
of the patients	14
the study at	14
each of these	14
is designed to	14
be due to	14
from the hospital	14
once daily for	14
the final version	14
described in the	14
the current study	14
and interpretation of	14
in patients who	14
patients who have	14
a serious adverse	14
nature of the	14
it is the	14
with the study	14
the conduct of	14
be provided by	14
from the patient	14
if there is	14
in the absence	14
high risk of	14
in preterm infants	14
in mechanically ventilated	14
by the patient	14
and treatment of	14
ward pilot rct	14
authors read and	14
to contact the	14
ethics committee of	14
a copy of	14
the exclusion criteria	14
these events will	14
secondary outcomes will	14
early intervention with	13
all authors read	13
ensure that the	13
the patient information	13
administration of the	13
the investigators will	13
the decision to	13
up to days	13
the trial has	13
of the subject	13
approval from the	13
as measured by	13
specified in the	13
was associated with	13
of chronic obstructive	13
the study was	13
safety monitoring board	13
in each group	13
the interim analysis	13
lung injury and	13
the hypothesis that	13
will be a	13
the implementation of	13
in the active	13
in the soa	13
if a patient	13
copy of the	13
with acute respiratory	13
be collected and	13
the study center	13
time during the	13
outcome will be	13
role in the	13
controlled trial of	13
the following criteria	13
will be estimated	13
discretion of the	13
evaluation of the	13
the patient has	13
trial steering committee	13
intervention and control	13
data protection regulation	13
in medical patients	13
the primary evaluation	13
will receive a	13
least one of	13
the inclusion and	13
the study site	13
would like to	13
in the following	13
within hours of	13
addition to the	13
should not be	13
aware of the	13
will be determined	13
be made available	13
the sponsor and	13
used in the	13
drafted the manuscript	13
in the past	13
that will be	13
relationship to the	13
the primary and	13
of the drug	13
fraction of inspired	13
significance level of	13
committee of the	13
will be enrolled	13
years of age	13
be randomized to	13
the data analysis	13
the miracle trial	13
type i error	13
to determine the	13
test will be	13
cox proportional hazards	13
about the study	13
of iloprost on	12
x b x	12
in our study	12
will be discontinued	12
a causal relationship	12
group will have	12
groups will be	12
of lopinavir ritonavir	12
the coordinating investigator	12
will be allowed	12
first days after	12
shown in fig	12
implementation of the	12
be used in	12
to the following	12
to detect a	12
to ensure that	12
has been used	12
we will also	12
on reasonable request	12
blood samples will	12
be blinded to	12
followed up for	12
the data protection	12
considered to be	12
any untoward medical	12
completion of therapy	12
signs and symptoms	12
stored in a	12
and days of	12
it may be	12
a maximum of	12
body surface area	12
used to compare	12
the frequency of	12
whichever comes first	12
study at any	12
author on reasonable	12
criteria for adverse	12
participant will be	12
the criteria for	12
a sample size	12
the responsibility of	12
informed about the	12
there is an	12
peking university first	12
expected to be	12
conduct of the	12
determined by the	12
be presented as	12
be able to	12
the purpose of	12
the trial was	12
university first hospital	12
therapy and follow	12
outcome is the	12
moderate to severe	12
adverse events will	12
the patient to	12
is shown in	12
total sample size	12
the primary objective	12
of therapy and	12
and symptoms of	12
be recorded on	12
and that the	12
he or she	12
the standard of	12
has not been	12
patient will be	12
institutional review board	12
as compared to	12
in the data	12
in hospitalized patients	12
this group will	12
mg kg day	12
is in the	12
rescue intervention strategy	12
by means of	12
to the patient	12
of venous thromboembolism	12
the consent form	12
the nature of	12
days after the	12
be considered as	12
be collected from	12
the ministry of	12
a number of	12
is to be	12
the data and	12
research ethics committee	12
group and the	12
of acute respiratory	12
healthcare workers with	11
ill patients with	11
primary endpoint is	11
differences in the	11
severe respiratory failure	11
until hospital discharge	11
be documented in	11
to account for	11
patients with sars	11
for use in	11
whether or not	11
submitted to the	11
for interventional trials	11
the kfsh rc	11
the most common	11
d and d	11
intervention with sargramostim	11
terminology criteria for	11
days of enrolment	11
health coaching sessions	11
for those who	11
duration of mechanical	11
patients enrolled in	11
blood gas analysis	11
the patients will	11
evaluate the effect	11
at all times	11
the day of	11
of medical sciences	11
prior to study	11
defined by the	11
will be no	11
for the following	11
can be found	11
subjects will be	11
model will be	11
and the study	11
all patients who	11
at day and	11
that there is	11
will be checked	11
the definition of	11
will be applied	11
be stratified by	11
in the medical	11
study if early	11
the steering committee	11
infusion of ravulizumab	11
mechanical ventilation and	11
are available from	11
in additional file	11
be published in	11
exclusion criteria are	11
be conducted at	11
in combination with	11
discharged from the	11
at the discretion	11
secondary outcomes include	11
versus days of	11
be provided to	11
if early intervention	11
and at the	11
are responsible for	11
at each site	11
be performed on	11
mg kg h	11
within the past	11
common terminology criteria	11
termination of the	11
risk of death	11
the ovid study	11
of icu stay	11
no role in	11
ae or sae	11
the study medication	11
the investigator is	11
and has been	11
to the full	11
d proportion of	11
randomized controlled trials	11
discharge from hospital	11
the date of	11
during the procedure	11
lavage de nez	11
breast cancer survivors	11
will be offered	11
primary outcome will	11
partial pressure of	11
adverse events and	11
weeks prior to	11
endoscopic retrograde cholangiopancreatography	11
to the use	11
ravulizumab will be	11
of the treatment	11
the principal investigators	11
the patient should	11
of the manuscript	11
details of the	11
is funded by	11
should be considered	11
will be maintained	11
general data protection	11
from day onwards	11
prise en charge	11
may not be	11
randomized to the	11
any time during	11
the past months	11
the day period	11
in children with	11
people with dementia	11
will be generated	11
as an ae	11
measured by the	11
patient is not	11
the secondary outcomes	11
compared to placebo	11
be assessed by	11
increased risk of	11
and to the	11
to improve the	11
the treatment group	11
not limited to	11
of the research	11
impact on the	11
clinical recovery time	10
total number of	10
will be defined	10
time to the	10
the time to	10
hospitalised with bronchiolitis	10
cystic fibrosis bronchiectasis	10
the intervention will	10
composition of the	10
in collaboration with	10
induced lung injury	10
is a large	10
at the study	10
for mechanical ventilation	10
randomized to receive	10
the main trial	10
and on day	10
be kept in	10
in the intention	10
have shown that	10
in the lung	10
of the protocol	10
all analyses will	10
will include the	10
be stored at	10
will be identified	10
of the icu	10
consent is obtained	10
be informed about	10
analyses will include	10
occurrence of each	10
lavages de nez	10
in clinical practice	10
during the course	10
be conducted as	10
will consist of	10
of the university	10
be found in	10
surface area once	10
obtained from all	10
level of peep	10
best supportive care	10
to allow for	10
defined as any	10
criteria will be	10
adverse event is	10
the intervention period	10
is the first	10
patients treated with	10
provided in the	10
au cours de	10
of asthma exacerbations	10
after the end	10
and new zealand	10
the adverse event	10
to severe respiratory	10
renal replacement therapy	10
fondation adolphe de	10
on the day	10
for a randomized	10
the data monitoring	10
becoming aware of	10
use of a	10
mg kg twice	10
and control groups	10
objective is to	10
study design and	10
if it is	10
to keep the	10
the length of	10
risk of developing	10
at risk of	10
baseline and at	10
infants hospitalised with	10
during the current	10
be given to	10
electronic case report	10
incidence of moderate	10
severe trauma patients	10
will be contacted	10
experimental and control	10
up visits will	10
in the prior	10
the declaration of	10
an interim analysis	10
the feasibility of	10
the participants will	10
the intervention is	10
area once daily	10
be recruited from	10
should be made	10
of the investigator	10
american society of	10
has been reported	10
to be completed	10
the standard protocol	10
results from the	10
respiratory syndrome coronavirus	10
of clinical trials	10
difference in the	10
the potential to	10
during the screening	10
kg twice daily	10
be informed that	10
sensitivity analyses will	10
within hours after	10
component of the	10
be randomly assigned	10
last infusion of	10
direct access to	10
treatment group and	10
in the clinical	10
the crf ecrf	10
patients with dementia	10
assigned to the	10
randomization stratification factor	10
the digital intervention	10
the active group	10
a dose of	10
as an adjunct	10
institutional affiliations the	10
within h of	10
the berlin definition	10
will be required	10
the acute respiratory	10
la prise en	10
for up to	10
the outcome of	10
on the same	10
pourcentage de patients	10
period of weeks	10
be collected for	10
the beginning of	10
discharge from the	10
patients infected with	10
to standard of	10
responsibility of the	10
funded by the	10
is that the	10
the patient and	10
severity of the	10
the event of	10
will be notified	10
sodium chloride injection	10
declaration of helsinki	10
adolphe de rothschild	10
in line with	10
of the two	10
of care in	10
associated with covid	10
and the data	10
tests will be	10
admission to the	10
to withdraw from	10
to the covid	9
which is a	9
be done by	9
for the use	9
on the other	9
institutes of health	9
be excluded from	9
part in the	9
recorded on the	9
by treatment group	9
to complete the	9
in a secure	9
please see the	9
as a binary	9
to measure the	9
day compared with	9
regression will be	9
days of randomization	9
is the most	9
the delivery room	9
the screening period	9
ravulizumab bsc will	9
of care for	9
positive pressure ventilation	9
used for the	9
with azithromycin and	9
by the presence	9
clinical course and	9
and adverse events	9
outcome of the	9
risk factor for	9
study intervention and	9
of each of	9
sargramostim mcg m	9
retrospective cohort study	9
aim of this	9
of childbearing potential	9
adult patients with	9
patients who die	9
interim analysis is	9
ethics committee and	9
the study as	9
according to local	9
on or before	9
to compare the	9
were involved in	9
defined as a	9
to meet the	9
and will not	9
is estimated that	9
data and safety	9
in healthcare workers	9
be analysed as	9
a binary outcome	9
will be screened	9
to test the	9
who cannot take	9
balance main rct	9
at least weeks	9
days number of	9
the intervention to	9
for patients who	9
by the sponsor	9
patients with the	9
sample will be	9
an improvement in	9
the study by	9
an assessment of	9
shortness of breath	9
be randomized in	9
primary analysis will	9
patient information sheet	9
of our study	9
the participating centers	9
reported in the	9
and control group	9
to be published	9
may be considered	9
for clinical trials	9
the protocol and	9
and their caregivers	9
end of study	9
unexpected serious adverse	9
category ordinal scale	9
with or without	9
is less than	9
national institutes of	9
trial has been	9
was registered on	9
are eligible for	9
procedure will be	9
to take part	9
en cas de	9
the immune system	9
duration of mv	9
all saes will	9
body mass index	9
effects of iloprost	9
an additional days	9
documents will be	9
of the above	9
associated molecular patterns	9
be completed by	9
dose ketamine infusion	9
next of kin	9
was approved by	9
randomised to the	9
vestibular function tests	9
due to covid	9
months after the	9
in this case	9
study eudract number	9
sartre study eudract	9
this clinical trial	9
red blood cells	9
of patients experiencing	9
as per the	9
a randomized clinical	9
provide informed consent	9
be approved by	9
from all participants	9
will be entered	9
effect of a	9
after the completion	9
the subject or	9
m body surface	9
randomisation will be	9
participating in the	9
polymerase chain reaction	9
performed by the	9
the importance of	9
more than hours	9
will be sent	9
days or until	9
will be reviewed	9
during this study	9
as defined in	9
review of the	9
of informed consent	9
for the duration	9
as determined by	9
de plus de	9
mcg m body	9
data safety monitoring	9
respiratory bacterial pathogens	9
which is not	9
flow nasal cannula	9
data on the	9
mechanical ventilatory support	9
of the sponsor	9
the intervention arm	9
a result of	9
the last patient	9
as the primary	9
to have a	9
given to the	9
months of the	9
be involved in	9
the treating physicians	9
will receive the	9
forms will be	9
participated in the	9
trial is to	9
the last infusion	9
is the proportion	9
pao fio ratio	9
in the primary	9
clinical trial registry	9
registered on april	9
must be reported	9
regardless of the	9
provided to the	9
acute exacerbation of	9
an increased risk	9
not related to	9
dose of ravulizumab	9
will be immediately	9
balance main trial	9
electronic data capture	9
will continue to	9
the eligibility criteria	9
until the end	9
will be developed	9
it is estimated	9
who will be	9
of the follow	9
first patient recruited	9
liver and kidney	9
compliance with the	9
to the occurrence	9
is a prospective	9
power to detect	9
with the protocol	9
no later than	9
if the subject	9
should be recorded	9
and acute respiratory	9
to the patients	9
sent to the	9
need for mechanical	9
the sponsor will	9
inclusion criteria are	9
will be repeated	9
on top of	9
chez les patients	9
be screened for	9
years or older	9
of public health	9
the control arm	9
severe air pollution	9
at least days	9
new zealand clinical	9
in case the	9
onset of symptoms	9
with the patient	9
of patients admitted	9
is the responsibility	9
and risk factors	9
the rescue intervention	9
is not considered	8
will use a	8
time of the	8
of patients that	8
for continuous variables	8
is required to	8
designed the study	8
serious adverse reaction	8
will be described	8
endpoint will be	8
to achieve a	8
the relationship in	8
with acute stroke	8
all adverse events	8
patients who at	8
lopinavir ritonavir and	8
versus usual care	8
the clinical trials	8
the world health	8
visits will be	8
current study are	8
severity of illness	8
patients included in	8
de patients ayant	8
the basis of	8
the study procedures	8
the study investigators	8
the process of	8
patients under critical	8
be identified by	8
be treated with	8
in adult patients	8
of the participants	8
acute respiratory failure	8
assess the efficacy	8
h after randomization	8
and safety monitoring	8
depending on the	8
min after the	8
at a dose	8
at high risk	8
visit will be	8
the first patients	8
be in the	8
is supported by	8
the study data	8
dietary quality and	8
or older with	8
length of icu	8
drugs will be	8
the schedule of	8
trial was registered	8
stored at the	8
for the first	8
when patients are	8
male or female	8
has also been	8
proactive prophylaxis with	8
an alternative explanation	8
medication will be	8
of vestibular function	8
drug will be	8
must be documented	8
contact with the	8
to provide informed	8
it is not	8
specialist cancer nurse	8
proportional hazards model	8
as a time	8
le traitement par	8
of hospital admission	8
plus de points	8
will be held	8
values will be	8
randomised controlled trials	8
not consistent with	8
the primary outcomes	8
the difference between	8
patients aged or	8
in hospitalised patients	8
of life in	8
level of significance	8
will be drawn	8
adverse event which	8
in the acute	8
used to assess	8
the fact that	8
is to evaluate	8
the complement system	8
and the patient	8
or the control	8
a review of	8
allocation will be	8
recommendations for interventional	8
progression of disease	8
the rm max	8
a retrospective cohort	8
whether the patient	8
in the protocol	8
the dmc will	8
admitted to hospital	8
east respiratory syndrome	8
effect of iloprost	8
of biological specimens	8
deviations from the	8
clinical characteristics of	8
all patients will	8
with a combination	8
in the same	8
those who cannot	8
will be filled	8
is provided in	8
withdrawn from the	8
the difference in	8
may lead to	8
be compared using	8
middle east respiratory	8
for the development	8
the study to	8
and it is	8
intubated on day	8
and statistical code	8
intensive care units	8
affiliations the authors	8
australia and new	8
investigators will be	8
will be completed	8
be defined as	8
skills to support	8
the treating clinician	8
must not be	8
be measured by	8
aged or older	8
as defined by	8
been approved by	8
the irb iec	8
carried out in	8
well as a	8
intervention to prevent	8
this is an	8
analyzed during the	8
endpoints will be	8
is a single	8
dose of mg	8
are associated with	8
stratified by intubated	8
analysed as a	8
the study treatment	8
conducted in accordance	8
activation of the	8
progressing to severe	8
during the intervention	8
investigational medicinal product	8
within days will	8
study protocol and	8
institute of health	8
systolic blood pressure	8
in ambulatory patients	8
at randomisation were	8
par le promoteur	8
results of this	8
who at randomisation	8
controlled clinical trial	8
aes will be	8
for critically ill	8
this is the	8
relevant to the	8
in the delivery	8
the other hand	8
in hospital records	8
with acute lung	8
are to be	8
from the protocol	8
calculated using the	8
information on the	8
of a clinical	8
or legally acceptable	8
lead to a	8
prophylaxis with azithromycin	8
patients who received	8
mashhad university of	8
of bubonic plague	8
not intubated on	8
of lung injury	8
we anticipate that	8
are currently no	8
of patients will	8
during nasal cpap	8
on how to	8
of the implementation	8
envelopes will be	8
member of the	8
relationship in time	8
opinion of the	8
allocated to the	8
results in death	8
one or more	8
because of the	8
there are currently	8
or not intubated	8
out of the	8
characterized by a	8
that are not	8
and secondary outcomes	8
before and after	8
in the presence	8
and duration of	8
at the beginning	8
must be recorded	8
guidelines for the	8
will be allocated	8
reported by the	8
the eminent intervention	8
in the united	8
be considered to	8
will be based	8
may be used	8
the original treatment	8
such as the	8
publication of the	8
the local ethics	8
of the sae	8
respiratory syncytial virus	8
the pao fio	8
and may be	8
part of a	8
eligible for inclusion	8
has the potential	8
are currently being	8
and the control	8
screened for eligibility	8
of care and	8
notified to the	8
of the interventions	8
recruitment is ongoing	8
under critical care	8
to ensure the	8
throughout the study	8
of patients are	8
the united states	8
will be trained	8
that the study	8
with acute hypoxic	8
by the local	8
of cytokine release	8
will use the	8
anticipated to be	8
des lavages de	8
institutional affiliations we	8
not be reported	8
clinically relevant bleeding	8
all participants will	8
intubated or not	8
the participants in	8
of enoxaparin sodium	8
at day will	8
if the study	8
low birth weight	8
be required to	8
primary endpoint will	8
university of medical	8
to the local	8
days of the	8
sample size and	8
into the study	8
patients ayant une	8
case of a	8
the total number	8
changes to the	8
hospitalised patients with	8
a x b	8
of alexion confidential	8
page of alexion	8
in a clinical	8
related quality of	8
with respect to	8
medical research council	8
in patients under	8
will be monitored	8
exclusion criteria will	8
and consent to	8
be assigned a	8
by intubated or	8
a clinical study	8
intervention group will	8
of the participating	8
discussed with the	7
of vte in	7
aes and saes	7
and activation of	7
is necessary to	7
is anticipated to	7
understanding of the	7
day treatment period	7
the treatment groups	7
and quality of	7
renal failure requiring	7
the first dose	7
assess the safety	7
of the coordinating	7
clinical practice guidelines	7
with the intervention	7
aerosolized dornase alfa	7
will occur in	7
sedation and analgesia	7
study physician will	7
safety of the	7
the data management	7
investigator will be	7
of standard of	7
the first patient	7
prep with hydroxychloroquine	7
respiratory tract infection	7
the opportunity to	7
to prevent one	7
effect of ravulizumab	7
patients are not	7
uncorrected axillary temperature	7
or other medical	7
role of the	7
high levels of	7
limited to the	7
of iv sargramostim	7
diet and pa	7
the ae crf	7
an increase in	7
be summarized by	7
at least months	7
be provided with	7
to severe acute	7
be based on	7
or their legal	7
patients have completed	7
or until hospital	7
the safety and	7
a variety of	7
both treatment groups	7
protocol version number	7
least years of	7
specimens will be	7
to obtain a	7
first h of	7
writing of the	7
of patients in	7
for the analysis	7
lower respiratory tract	7
arm will be	7
high flow oxygen	7
in the live	7
as the date	7
beginning of the	7
description of the	7
dans le cadre	7
days after enrollment	7
continue to be	7
for the management	7
be notified to	7
the university hospital	7
and chest x	7
risk of sars	7
the procedure will	7
will be two	7
patient can be	7
with severe pneumonia	7
treatment with sargramostim	7
we plan to	7
and out of	7
on the treating	7
of the informed	7
all participating centers	7
but will be	7
included in this	7
all of the	7
patients may be	7
before the start	7
the assessment of	7
plus soc for	7
in this clinical	7
report will be	7
will have a	7
of patients is	7
associated with an	7
interim analysis of	7
be limited to	7
any hospitalization or	7
care in the	7
follow up visit	7
option to receive	7
found that the	7
kg body weight	7
hiruz ctu will	7
provided with standard	7
factors associated with	7
days of iv	7
will recruit patients	7
h of life	7
acutely ill medical	7
statistical analyses will	7
and any other	7
to the treatment	7
the quality of	7
the relationship between	7
representative will be	7
to be an	7
prevent one of	7
be considered in	7
with the data	7
in the national	7
the trial in	7
the implementation process	7
temporal relationship to	7
days prior to	7
or pao fio	7
university of southampton	7
treatment for covid	7
aspects of the	7
out of hospital	7
assigned the value	7
to the data	7
is a common	7
is not consistent	7
by the principal	7
investigator is responsible	7
aged years or	7
when the patient	7
of hospital stay	7
on the basis	7
in the incidence	7
of the declaration	7
we are conducting	7
the benefits of	7
soc for covid	7
given the current	7
diagnosis and treatment	7
is one of	7
pwds and their	7
the help of	7
large number of	7
measurements will be	7
will follow the	7
the majority of	7
study intervention or	7
study will also	7
within the last	7
similar to the	7
of which is	7
for a period	7
loss to follow	7
up period d	7
the hypothesis of	7
studies have shown	7
medical patients with	7
azithromycin and hydroxychloroquine	7
in the ae	7
caused by the	7
involved in data	7
the same time	7
severity of which	7
based on all	7
of data collection	7
wilcoxon rank sum	7
in all cases	7
results of a	7
the alternative hypothesis	7
the recommended dose	7
will ensure that	7
be assigned the	7
the gut microbiota	7
days of treatment	7
listed in table	7
neutrophil extracellular traps	7
may also be	7
days of antibiotic	7
the p f	7
analysis is planned	7
is due to	7
that the use	7
cluster randomized controlled	7
of the respiratory	7
take part in	7
of study data	7
respiratory failure and	7
asthma assessment scales	7
of the final	7
the epidemiological impact	7
will be censored	7
participation in this	7
will be constructed	7
parameters will be	7
who die within	7
study is conducted	7
records may be	7
of the statistical	7
size of patients	7
and as a	7
registered on march	7
signed and dated	7
the participant will	7
distress syndrome in	7
the patient or	7
sarilumab will be	7
approval and consent	7
the electronic data	7
noted in the	7
the following variables	7
colony stimulating factor	7
patients suffering from	7
pressure of oxygen	7
days alive and	7
progression to renal	7
failure requiring dialysis	7
of the treating	7
in intensive care	7
a randomized trial	7
of the nasal	7
the health of	7
the order of	7
will be replaced	7
flow nasal oxygen	7
the dsmb will	7
the study has	7
be replaced by	7
be presented by	7
ae crf ecrf	7
we therefore believe	7
will be left	7
be responsible for	7
visual analogue scale	7
between the intervention	7
missing data will	7
application of a	7
for the pwd	7
for intubation and	7
study aims to	7
the study should	7
patients in each	7
eligible patients will	7
the funding body	7
top of standard	7
date and time	7
will receive an	7
to protect the	7
the clinical recovery	7
their legally acceptable	7
department of health	7
in patients undergoing	7
signed by the	7
early breast cancer	7
part of routine	7
be presented for	7
will be limited	7
information and consent	7
on the appropriate	7
of personal data	7
and or ards	7
the european union	7
consent was obtained	7
care for the	7
intention to treat	7
jun page of	7
local ethics committee	7
to renal failure	7
will be treated	7
difference between the	7
between day and	7
but are not	7
schools will be	7
patients randomised to	7
patients aged years	7
de la perte	7
will be responsible	7
by the investigators	7
safety profile of	7
and death in	7
or inability to	7
a comparison of	7
associated with acute	7
the nature and	7
bsc alone on	7
mean arterial pressure	7
the burden of	7
and severity of	7
b x c	7
must also be	7
the distribution of	7
of the other	7
cluster randomised controlled	7
serious adverse reactions	7
edta blood sample	7
and for the	7
c x x	7
bronchiolitis in indigenous	7
free days number	7
so that the	7
or in the	7
adherence to the	7
society of hematology	7
with a deviated	7
will be tested	7
and reported to	7
protocol will be	7
alive and out	7
ethics approval and	7
study are available	7
collected at the	7
will be set	7
to be used	7
are able to	7
left to the	7
pao fio below	7
assess the effect	7
the cytokine storm	7
access to all	7
will evaluate the	7
be invited to	7
lung injury in	7
be sent to	7
lead to improved	7
exacerbation of copd	7
the trial steering	7
the source documents	7
in elderly patients	7
and the trial	7
pneumoniae and chlamydia	7
have completed the	7
the same household	7
collect peripheral blood	7
the caloric test	7
collaboration with the	7
versus medical management	7
be collected in	7
take place in	7
of the covid	7
the last days	7
epidemiological impact of	7
f ratio is	7
national cancer institute	7
to mechanical ventilation	7
and development of	7
serum blood sample	7
is not applicable	7
followed by ciprofloxacin	7
die within days	7
day mortality rate	7
required for the	7
completed the study	7
ten days or	7
alternative hypothesis is	7
we would like	7
and chlamydia species	7
changes in the	7
study has been	7
invasive mechanical ventilatory	7
the conclusion of	7
control group and	7
eligibility criteria for	7
study participants will	7
following this posology	7
the specialist cancer	7
dans le groupe	7
in cancer patients	7
can lead to	7
idiopathic sudden sensorineural	7
and no later	7
practice in the	7
criteria for the	7
and informed consent	7
the manuscript for	7
the intervention clinician	7
compared to standard	7
a decrease in	7
data collection and	7
in at least	7
defined as an	7
will be labelled	7
patients who meet	7
the medical records	7
the study for	7
numbers of patients	7
number of covid	7
a patient is	7
asthma exacerbations per	7
a power of	7
a deviated septum	7
after completion of	7
date of the	7
mechanically ventilated patients	7
death in patients	7
sample size was	7
to the hospital	7
course and risk	6
will include a	6
nasal continuous positive	6
in the reference	6
will participate in	6
efficacy of the	6
a congenital anomaly	6
to the administration	6
procedures will be	6
of antibiotic treatment	6
daily for those	6
of days within	6
the association between	6
will be destroyed	6
binary logistic regression	6
sequence will be	6
data in the	6
up to mg	6
in the best	6
of ctcae ratings	6
relating to the	6
all serious adverse	6
by an independent	6
the evaluation of	6
the sponsor is	6
medical occurrence that	6
are blinded to	6
of budesonide formoterol	6
below on minimal	6
cannot take oral	6
be recorded as	6
single iv injection	6
disseminated intravascular coagulation	6
of this intervention	6
objective of the	6
enrolled in this	6
will be an	6
first year of	6
of adjunct low	6
admission or death	6
validation of the	6
must be informed	6
compared with placebo	6
peripheral capillary oxygen	6
the results will	6
of the nose	6
is characterized by	6
for management of	6
participation is voluntary	6
primary endpoint of	6
of the lung	6
synbiotic supplementation on	6
taking part in	6
and intensive care	6
to stop the	6
models will be	6
the nairos trial	6
to be recruited	6
in which patients	6
be considered serious	6
iv twice daily	6
day period is	6
number of participants	6
the findings of	6
icu patients with	6
there are two	6
the placebo group	6
total duration of	6
is to assess	6
in which the	6
in time is	6
are included in	6
a multicomponent intervention	6
who wish to	6
feasibility of the	6
as early as	6
the context of	6
shown in table	6
median and interquartile	6
of study intervention	6
with standard hygiene	6
of the medical	6
across the globe	6
days within the	6
the comparison of	6
the trial statistician	6
and at least	6
the exception of	6
for detection of	6
to study drug	6
this intervention is	6
the following events	6
at day compared	6
university of oxford	6
the most important	6
are used to	6
by the caregiver	6
be made to	6
event rate in	6
pneumonia in wuhan	6
before d proportion	6
and the first	6
confirmed by recent	6
to ensure a	6
consent from the	6
of the information	6
negative pregnancy test	6
as there is	6
be done using	6
report for publication	6
to the intensive	6
the study population	6
food and drug	6
children with bronchiectasis	6
to perform a	6
will be randomised	6
in the analysis	6
analyzed using a	6
points au score	6
the details of	6
on the foreseeable	6
by using the	6
for mortality of	6
of the randomization	6
failure to ards	6
in the early	6
g kg min	6
considered as a	6
has to be	6
the final report	6
bronchiectasis exacerbations in	6
will be approved	6
the nature or	6
adverse event on	6
consists of a	6
currently being hospitalized	6
the icu units	6
foreseeable overflow of	6
in the source	6
will be eligible	6
to the nature	6
dosed with ravulizumab	6
event on or	6
be asked for	6
the research nurse	6
will reduce the	6
rank sum test	6
additional days of	6
will be retained	6
increase the risk	6
mortality rate of	6
and a follow	6
of the national	6
of product characteristics	6
respiratory illness in	6
staff will be	6
infected patients that	6
day intervention with	6
a subset of	6
blood will be	6
to the investigator	6
primary end point	6
we will not	6
shown to reduce	6
with conventional therapy	6
the investigator to	6
between d and	6
mortality of adult	6
are conducting a	6
conducted according to	6
suspected unexpected serious	6
into the trial	6
used in clinical	6
will be sought	6
entered into the	6
children will be	6
need to be	6
of the live	6
for ten days	6
have a huge	6
will receive placebo	6
with dementia and	6
case report forms	6
the selection of	6
due to a	6
resolution of fever	6
on the following	6
national institute of	6
duration of hospitalization	6
igm and igg	6
the trial for	6
point ordinal scale	6
evaluate differences in	6
with confidence interval	6
patients per group	6
months prior to	6
white blood cell	6
throughout the trial	6
not have any	6
endpoint is the	6
ards could have	6
will be called	6
inclusion in the	6
at the university	6
ill medical patients	6
for people with	6
maximal value and	6
will be prepared	6
be transferred to	6
study if treatment	6
a clinical trial	6
duration of icu	6
the main secondary	6
after the onset	6
in the context	6
cure rct is	6
sharing is not	6
ravulizumab bsc compared	6
of the pregnancy	6
respiratory system elastance	6
risk of secondary	6
effects of the	6
to the central	6
after the injection	6
treatment of ards	6
the live intervention	6
respiratory tract infections	6
objectives of the	6
and mechanical ventilation	6
patients with confirmed	6
the patients in	6
at the site	6
in the patient	6
patients with copd	6
in patients in	6
with the help	6
indigenous infants hospitalised	6
ethical committee of	6
signs of cytokine	6
patients have been	6
the foreseeable overflow	6
alexion or designee	6
clinical trial with	6
ritonavir and interferon	6
are required to	6
informed consent is	6
in adults with	6
be conducted on	6
with inhaled sargramostim	6
an ae or	6
study site staff	6
in the management	6
and at and	6
the trial sponsor	6
will be adjusted	6
number will be	6
time in the	6
maximal increase in	6
receive an additional	6
in the uk	6
with the sponsor	6
of versus days	6
active group will	6
of bronchiolitis in	6
to patients with	6
excluded from the	6
a cohort of	6
all patients at	6
will not have	6
peep cmh o	6
evaluate the efficacy	6
outside of the	6
the coordinator will	6
current standard of	6
for early breast	6
defined in the	6
focused on the	6
if a subject	6
comply with the	6
safety of sarilumab	6
an average of	6
and standard deviation	6
to examine the	6
of death or	6
also be reported	6
the critical care	6
to receive either	6
change from baseline	6
icu admission or	6
who meet the	6
a cluster randomised	6
treatment success after	6
with the exception	6
conducted at the	6
has been obtained	6
will be placed	6
calculated from the	6
after the first	6
a lack of	6
persons with dementia	6
or before d	6
be discussed with	6
is considered to	6
described in this	6
mean and standard	6
categorical variables will	6
on blood pressure	6
the requirements of	6
after initiation of	6
randomisation were in	6
the prevalence of	6
with sargramostim affects	6
au score odoratest	6
and designed the	6
database will be	6
secondary outcomes are	6
standard hygiene requirements	6
will compare the	6
been used for	6
a member of	6
experiencing a serious	6
in selected centers	6
mild general covid	6
version to be	6
sponsor and principal	6
that the patient	6
group compared to	6
who received the	6
in the model	6
huge impact on	6
and respiratory failure	6
two study groups	6
regression models for	6
of vestibular dysfunction	6
primary outcomes are	6
of the p	6
elderly patients with	6
in the elderly	6
after days of	6
will be delivered	6
the list of	6
in writing the	6
and during the	6
hospitalized across the	6
used to identify	6
safety and efficacy	6
the opinion of	6
summary of product	6
participants will receive	6
in the northern	6
give access to	6
during this trial	6
factors for mortality	6
will be invited	6
data must be	6
study data will	6
test for sars	6
subject or legally	6
our hypothesis is	6
the day visit	6
trial is a	6
adverse events are	6
in some patients	6
clinical and laboratory	6
white blood cells	6
to do so	6
sponsor and the	6
arm will receive	6
no exclusion criteria	6
from the icu	6
seen in the	6
trial master file	6
scores at day	6
la date de	6
of respiratory symptoms	6
blinded to group	6
subgroup analyses will	6
during the follow	6
aim of the	6
and there is	6
study and the	6
pour les patients	6
and the presence	6
antibiotic therapy for	6
hospitalization or all	6
for the purpose	6
records will be	6
by the use	6
be determined by	6
vast majority of	6
in this open	6
of screen failure	6
intravenously following this	6
size will be	6
the ris group	6
be called group	6
of respiratory distress	6
of fudan university	6
accompanying person from	6
a trial of	6
of ravulizumab bsc	6
observed in the	6
to investigate the	6
method will be	6
respiratory failure to	6
x c x	6
months from the	6
that can be	6
be administered intravenously	6
medical ethics committee	6
effectiveness of a	6
can only be	6
mechanical ventilation at	6
minimal l min	6
in the critical	6
be documented on	6
are shown in	6
indigenous australian infants	6
will be undertaken	6
the trial master	6
the vast majority	6
analysis and interpretation	6
standard supportive care	6
performed at the	6
that are currently	6
the first year	6
study was approved	6
value and maximal	6
the same as	6
of pao fio	6
and secondary endpoints	6
as a single	6
in patients treated	6
be reported in	6
for the current	6
personne qui se	6
binary outcome and	6
study should be	6
of coronavirus disease	6
the k th	6
be associated with	6
controlled trial with	6
be left to	6
be related to	6
bsc compared with	6
collected during the	6
the prep group	6
of treatment success	6
during the entire	6
reported as an	6
with confirmed covid	6
exacerbations of chronic	6
of more than	6
of lost to	6
by recent laboratory	6
but not limited	6
burden of disease	6
for breast cancer	6
for human use	6
and can be	6
chronic kidney disease	6
review and approval	6
any adverse event	6
if treatment with	6
or until discharge	6
to the experimental	6
to the development	6
in a locked	6
definition of serious	6
reliability of ctcae	6
is an open	6
is a multicenter	6
the medical monitor	6
as probable covid	6
randomized in a	6
to comply with	6
a range of	6
red blood cell	6
the protocol will	6
specialists and gps	6
period of time	6
traditional chinese medicine	6
statistics will be	6
be presented in	6
with standard supportive	6
glasgow coma scale	6
interim analysis will	6
or analyzed during	6
to be collected	6
be calculated for	6
progressive patients in	6
be generated by	6
is not possible	6
adult inpatients with	6
until the day	6
of respiratory viruses	6
outcome and as	6
more than h	6
a huge impact	6
collected at baseline	6
of the complement	6
diastolic blood pressure	6
the northern territory	6
asked to sign	6
of adult inpatients	6
intervention with inhaled	6
will be transferred	6
patients do not	6
development of a	6
risk of vte	6
and maximal increase	6
is planned to	6
developed by the	6
participating in this	6
be given the	6
must be collected	6
of copd exacerbation	6
of the participant	6
de points au	6
the entire study	6
of severe acute	6
international conference on	6
is unable to	6
period is reached	6
capillary oxygen saturation	6
from the main	6
to the participating	6
at each study	6
between the study	6
to an event	6
on mechanical ventilation	6
patients experiencing a	6
there are several	6
be recorded and	6
and interquartile range	6
for participation in	6
health of the	6
may reduce the	6
at a later	6
score on the	6
the allocation sequence	6
on minimal l	6
trial is funded	6
in the current	6
do not receive	6
patients progressing to	6
be collected during	6
prior to randomisation	6
venous thromboembolism in	6
en lavage de	6
patients will only	6